Published in Oncotarget on July 12, 2016
Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Front Physiol (2017) 0.75
Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. Front Physiol (2016) 0.75
The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia. Front Physiol (2017) 0.75
What Can be Learned from the Time Course of Changes in Low-Frequency Stimulated Muscle? Eur J Transl Myol (2017) 0.75
Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci Rep (2017) 0.75
NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (2009) 67.17
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
BFAST: an alignment tool for large scale genome resequencing. PLoS One (2009) 7.48
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol (2011) 4.95
Induction of cachexia in mice by systemically administered myostatin. Science (2002) 4.39
Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol (2004) 2.58
Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr (2012) 2.14
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol (2010) 1.91
Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care (2005) 1.73
STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One (2011) 1.61
Amelioration of lipid-induced insulin resistance in rat skeletal muscle by overexpression of Pgc-1β involves reductions in long-chain acyl-CoA levels and oxidative stress. Diabetologia (2011) 1.59
Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun (2009) 1.45
ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. Cell Signal (2006) 1.41
Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal (2011) 1.34
Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One (2010) 1.31
NGSUtils: a software suite for analyzing and manipulating next-generation sequencing datasets. Bioinformatics (2013) 1.28
Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg (2003) 1.28
Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol (2012) 1.27
Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med (2015) 1.27
Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Cancer Res (2006) 1.26
Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat Commun (2015) 1.21
C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J (2011) 1.19
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
Elevated expression of activins promotes muscle wasting and cachexia. FASEB J (2013) 1.13
Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest (2008) 1.11
Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol (2013) 1.09
Body surface area prediction in normal, hypermuscular, and obese mice. J Surg Res (2008) 1.07
Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology (2007) 1.06
Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol Appl Pharmacol (2010) 1.04
Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem (2015) 1.03
Development of a mouse model for assessing fatigue during chemotherapy. Comp Med (2011) 1.02
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome. Br J Cancer (2013) 1.02
Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets (2009) 1.01
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer (2012) 1.01
Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor γ coactivator 1α. J Recept Signal Transduct Res (2010) 1.01
Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care (2011) 1.00
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One (2008) 0.99
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol (2014) 0.99
Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. J Cachexia Sarcopenia Muscle (2012) 0.97
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle (2011) 0.95
Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle (2015) 0.95
Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. Biomed Pharmacother (2013) 0.94
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer (2014) 0.94
Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine (2002) 0.92
Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J Cell Physiol (2014) 0.92
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta (2013) 0.91
Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology (2013) 0.91
Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum (2009) 0.91
Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist (2012) 0.89
The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic Biol Med (2013) 0.88
Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. Hum Mol Genet (2015) 0.87
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis (2010) 0.87
Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS One (2010) 0.87
Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology (2014) 0.86
Cigarette smoke-induced skeletal muscle atrophy is associated with up-regulation of USP-19 via p38 and ERK MAPKs. J Cell Biochem (2011) 0.85
Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α. Amino Acids (2010) 0.85
Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY) (2012) 0.84
Skeletal muscle atrophy is attenuated in tumor-bearing mice under chemotherapy by treatment with fish oil and selenium. Oncotarget (2015) 0.83
Attenuation of skeletal muscle atrophy via protease inhibition. J Appl Physiol (1985) (2005) 0.83
The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer. Anticancer Res (2010) 0.82
Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism (1995) 0.82
Assessment of muscle mass and strength in mice. Bonekey Rep (2015) 0.81
A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. J Cachexia Sarcopenia Muscle (2015) 0.81
Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget (2015) 0.79
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis. Ther Drug Monit (2016) 0.75